## Records ?

## **Pediatric Thoracic Transplant Recipient Follow-Up Worksheet**

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI<sup>B.</sup> application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI<sup>B.</sup> application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
Previous Follow-Up:	Previous Px Stat Date:
Transplant Discharge Date:	
State of Permanent Residence: *	
Zip Code: *	
Provider Information	
Recipient Center:	
Followup Center:	
Physician Name: *	
NPI: *	
	Transplant Center
	Non Transplant Center Specialty Physician
Follow-up Care Provided By: ★	Primary Care Physician
	Cother Specify
	Cities opening
Specify:	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Patient Status	
Date: Last Seen, Retransplanted or Death *	
	LIVING
Patient Status: *	© DEAD
Tallott Status.	
	© RETRANSPLANTED
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	
Specify:	
ореспу.	
Contributory Cause of Death:	
Specify:	
0,000,000	
Hospitalizations:	
Has the patient been hospitalized since the last patient status date: *	YES NO UNK
Number of Hospitalizations:	St=
Hospitalized for Rejection:	C YES ONO UNK
Hospitalized for Infection:	C YES NO UNK
Noncompliance:	
Was there evidence of noncompliance with immunosuppression medication during this follow-up period that compromised the patient's recovery:	© YES © NO © UNK
-	
Functional Status: *	

	<ul> <li>Definite Cognitive delay/impairment (verified by IQ score &lt;70 or unambiguous behavioral observation)</li> </ul>				
	Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)				
Cognitive Development: *	Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties)				
	<ul> <li>No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment)</li> </ul>				
	Not Assessed				
	Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation)				
Motor Development: *	Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence)				
	Questionable Motor delay/impairment (not judged to be more likely than not, but with some indications of				
	motor delay/impairment)  No Motor delay/impairment (no obvious indicators of motor delay/impairment)				
	Not Assessed				
	- Not Assessed				
	Within One Grade Level of Peers				
	C Delayed Grade Level				
Academic Progress: *	Special Education				
	Not Applicable < 5 years old				
	Status Unknown				
	Full academic load				
	Reduced academic load				
Academic Activity Level: *	Unable to participate in academics due to disease or condition				
	Not Applicable < 5 years old/ High School graduate				
	Status Unknown				
Primary Insurance at Follow-up: *					
Specify					
Clinical Information					
Date of Measurement: *					
Height: ★	ft. in. cm %ile ST=				
Weight: *	lbs. kg %ile ST=				
BMI:	kg/m <sup>2</sup> %ile				
Graft Status: *	Functioning Failed				
If death is indicated for the recipient, and the death was a result of some other	her factor unrelated to graft failure, select Functioning.				
Date of Graft Failure:					
	Primary Non-Function				
Primary Cause of Graft Failure:	C Acute Rejection				
Filliary Gause of Graft Failure.	Chronic Rejection/Atherosclerosis				
	Other specify				
Other, Specify:					
Titer Information:					
	Current B Titer Sample Date				
	Current A Titer Sample Date				
Graft Function:					
Heart:					
Ejection Fraction: *	% ST=				
Shortening Fraction: *	% ST=				
Pacemaker: *	C YES ONO UNK				

Coronary Artery Disease: *	C YES NO UNK			
Clinically Significant Events:	C YES O NO UNK			
Lung:				
FeV1: *	% ST=			
O2 Requirement at Rest: *	L/min ST=			
	© NO BOS			
	Yes, Grade OP			
Bronchiolitis Obliterans Syndrome: *	<ul><li>Yes, Grade 1</li><li>Yes, Grade 2</li></ul>			
Bronomondo Osmerano Oynarome.	Yes, Grade 3			
	Yes, Grade UNK			
	C Unknown			
Bronchial Stricture (Since last follow-up): *	C YES NO UNK			
If yes, Stent:	G YES G NO G UNK			
Post Transplant Events:				
Drug Treated Hypertension:	C YES O NO UNK			
Bone Disease (Symptomatic):	C YES O NO UNK			
Chronic Liver Disease:	C YES O NO UNK			
Cataracts:	C YES C NO C UNK			
Diabetes onset during the follow-up period: *	C YES C NO C UNK			
Diabetes: If Yes, Insulin Dependent:	C YES C NO C UNK			
Renal Dysfunction: *	C YES C NO C UNK			
If Yes, Creatinine > 2.5 mg/dl:	G YES NO G UNK			
Chronic Dialysis:	G YES NO UNK			
Renal Tx since Thoracic Tx:	C YES NO UNK			
Stroke:	G YES G NO G UNK			
Drug Treated Hyperlipidemia:	C YES C NO C UNK			
	Yes, at least one episode treated with anti-rejection agent			
	Yes, none treated with additional anti-rejection agent  Yes, none treated with additional anti-rejection agent			
Did patient have any acute rejection episodes during the follow-up period: *	© No			
	Unknown			
	Biopsy not done			
	Yes, rejection confirmed			
Was biopsy done to confirm acute rejection:	Yes, rejection not confirmed			
	© Unknown			
Postransplant Malignancy: *	© YES © NO © UNK			
Donor Related:	© YES © NO © UNK			
Recurrence of Pre-Tx Tumor:	© YES © NO © UNK			
De Novo Solid Tumor:	© YES © NO © UNK			
De Novo Lymphoproliferative disease and Lymphoma:	© YES © NO © UNK			

Biological or Anti-viral therapy:	C YES NO Unknown/Canr	not disclose		
	Acyclovir (Zovirax)			
	Cytogam (CMV)			
	Gamimune			
	Gammagard			
	Ganciclovir (Cytovene)			
If Yes, check all that apply:	☐ Valgancyclovir (Valcyte)			
	HBIG (Hepatitis B Immune Globe	ılin)		
	Flu Vaccine (Influenza Virus)			
	Lamivudine (Epivir) (for treatme	nt of Hepatitis B)		
	☐ Valacyclovir (Valtrex)			
	Other, Specify			
Specify:				
Specify:				
Other therapies:	C YES NO			
	Photopheresis			
If Yes, check all that apply:	Plasmapheresis			
ii 165, oncok ali tilat appiy.	Total Lymphoid Irradiation (TLI)			
	Total Lymphold madiation (12)			
Immunosuppressive Information				
Previous Validated Maintenance Follow-Up Medications:				
	Yes, same as previous validated	report		
Were any medications given during the follow-up period for maintenance:	Yes, but different than previous			
*	None given	vandatod roport		
Did the physician discontinue all maintenance immunosuppressive medications:	C YES C NO			
medications.				
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES NO			
Specify:				
Immunosuppressive Medications  View Immunosuppressive Medications				
The William Couppies Sive Medications				
Definitions Of Immunosuppressive Follow-Up Medications				
For each of the immunosuppressant medications listed, check <b>Previous Mainten</b>	ance (Prev Maint), Current Maintenance	e (Curr Maint) or Anti-rejec	tion (AR) to indicate al	I medications that were
prescribed for the recipient during this follow-up period, and for what reason. If a representation Previous Maintenance (Prev Maint) includes all immunosuppressive medication	medication was not given, leave the assoc	iated box(es) blank.	, ,	
periods of time which may be either long-term or intermediate term with a tapering Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Azathioprine, or R	g of the dosage until the drug is either elim	inated or replaced by anoth	er long-term maintenar	nce drug (example:
Current Maintenance (Curr Maint) includes all immunosuppressive medications intermediate term with a tapering of the dosage until the drug is either eliminated	given at the current clinic visit to begin in	the next report for varying po	eriods of time which ma	ay be either long-term or
Mofetil, Azathioprine, or Rapamycin). This does not include any immunosuppress	ive medications given to treat rejection epi	sodes.		
Anti-rejection (AR) immunosuppression includes all immunosuppressive medica Atgam, OKT3, or Thymoglobulin). When switching maintenance drugs (example: not be listed under AR immunosuppression, but should be listed under maintenance drugs (example: not be listed under AR immunosuppression, but should be listed under maintenance drugs (example: not be listed under AR immunosuppression).	from Tacrolimus to Cyclosporine; or from I	acute rejection episode since Mycophenolate Mofetil to Az	e the last clinic visit (exact athioprine) because of	ample: Methylprednisolone, rejection, the drugs <u>should</u>
Note: The Anti-rejection field refers to any anti-rejection medications since to	the last clinic visit, not just at the time of		Material AB	han ber
If an immunosuppressive medication other than those listed is being administered Medication field, and enter the full name of the medication in the space provided.	n (e.g., new monoclonal antibodies), select  Do not list non-immunosuppressive me	Previous Maint, or Current edications.	viaint, or AR next to Ot	ner immunosuppressive
		Daniel M. C.	Our Market	AD
Steroids (Prednisone, Methylprednisolone, Solumedrol, Medrol, Decadron)		Prev Maint	Curr Maint	AR
Atgam (ATG)		_		
OKT3 (Orthoclone, Muromonab)			_	
Thymoglobulin				
Simulect - Basiliximab				
Zenapax - Daclizumab			_	
		-	. —	

EON (Generic Cyclosporine)			
Gengraf (Abbott Cyclosporine)			
Other generic Cyclosporine, specify brand:			
Neoral (CyA-NOF)			
Sandimmune (Cyclosporine A)			
Mycophenolate Mofetil (MMF, Cellcept, RS61443)			
Tacrolimus (Prograf, FK506)			
Modified Release Tacrolimus FK506E (MR4)			
Sirolimus (RAPA, Rapamycin, Rapamune)			
Myfortic (Mycophenolate Sodium)			
Other Immunosuppressive Medications			
	Prev Maint	Curr Maint	AR
Campath - Alemtuzumab (anti-CD52)			
Campath - Alemtuzumab (anti-CD52)  Cyclophosphamide (Cytoxan)			
Cyclophosphamide (Cytoxan)			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify  Rituximab			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify  Rituximab			
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify  Rituximab  Investigational Immunosuppressive Medications	Prev Maint	Curr Maint	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
Cyclophosphamide (Cytoxan)  Leflunomide (LFL, Arava)  Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)  Other Immunosuppressive Medication, Specify  Other Immunosuppressive Medication, Specify  Rituximab  Investigational Immunosuppressive Medications  Everolimus (RAD, Certican)	Prev Maint	Curr Maint	AR

Azathioprine (AZA, Imuran)